All In Biotech

Free tool

FAERS Monitor: Pataday Twice Daily Relief

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 020688 or its brand name (Pataday Twice Daily Relief, Olopatadine Hydrochloride). Reports on generic versions are filed under their own applications.

Reports

4,235

Serious

1,367

32% of reports

Hospitalization

787

Death reported

195

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • treatment failure1,934
  • drug ineffective315
  • headache123
  • nausea117
  • diarrhoea114
  • fatigue104
  • pyrexia104
  • pneumonia103
  • malaise99
  • rash98
  • pruritus95
  • dyspnoea92
  • pain92
  • cough89
  • eye irritation85

Reports by year received

View as table
YearReports
20046
200510
20065
20078
200817
200918
201026
201125
201224
201330
201429
201549
201682
201791
2018131
2019191
20201,938
2021365
2022216
2023220
2024244
2025255
2026255

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,049,924 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
treatment failureSignal1,934118.7114.8221,181
eye irritationSignal857.35.9460
pneumonia1031.61.322
cough891.61.318
pyrexia1041.51.217
pruritus951.21.04
drug ineffective3151.21.110
malaise991.10.91
rash981.10.91
headache1231.00.80
diarrhoea1140.90.72
dyspnoea920.80.74
pain920.70.68
nausea1170.70.611
fatigue1040.70.518

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.